The FDA has approved the supplemental Biologics License Application (sBLA) for Fluzone High-Dose Quadrivalent for active immunization for the prevention of influenza disease in patients aged ≥65 years.
Baloxavir marboxil was well-tolerated in a pediatric population and rapidly reduced viral titers.
The FDA has approved a supplemental NDA for Xofluza for the treatment of acute, uncomplicated influenza in patients aged 12 years and older.
Although the risk for hospitalization with influenza was higher in patients with type 2 diabetes, mortality rates were lower.
Influenza A(H3) is predominating in many regions in Southern Hemisphere while influenza activity remains low in the United States.
Influenza vaccination can be modestly effective in reducing laboratory-confirmed influenza-associated hospitalizations in people with chronic obstructive pulmonary disease.
Vaccine knowledge and anticipated rates of vaccination are even lower for pneumococcal disease.
Cost savings could include reductions in respiratory tract infections, antibiotic prescriptions, and sick days.